Dasatinib is a tyrosine kinase inhibitor used to treat certain types of leukemia [1]. The patent CN1348370A is related to a preparation method for dasatinib [2].
What is the status of patents for dasatinib?
The patent CN1348370A is a Chinese invention patent application published on December 24, 2003. It details a specific method for preparing dasatinib, which is crucial for its manufacturing [2]. Information on the current status and expiry of dasatinib patents, including this specific one and others globally, can be found on DrugPatentWatch.com [3].
What does patent CN1348370A cover?
This patent application, CN1348370A, describes a method for preparing dasatinib and its intermediate products. The method aims to improve the purity and yield of the active pharmaceutical ingredient [2].
How is dasatinib used in medicine?
Dasatinib is prescribed to patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1]. It works by blocking the action of abnormal proteins that promote cancer cell growth [1].
Where can I find more information about dasatinib patents?
DrugPatentWatch.com provides a comprehensive database of drug patents, including those for dasatinib. This resource can help track patent expiry dates, identify generic competitors, and understand patent litigation related to specific drugs [3].
What are the potential implications of expired dasatinib patents?
When patents for drugs like dasatinib expire, it typically opens the door for generic manufacturers to produce and sell their own versions of the medication. This often leads to increased competition and lower drug prices for patients and healthcare systems [3].
Sources:
[1] https://www.cancer.gov/drugdictionary/retail/1000212
[2] https://patents.google.com/patent/CN1348370A/en
[3] https://drugpatentwatch.com/